| Metric | Value ($ M) | Q1 FY25 |
|---|---|---|
| Revenue | 14.00 | 0.4% |
| Total Income | 14.00 | 0.4% |
| Expenditure | 14.52 | 14.1% |
| PBT | -0.45 | 133.8% |
| Net Profit | -0.44 | 133.6% |
| OPM | -3.77% | 13.22pp |
| NPM | -3.12% | 12.45pp |
| EPS | -0.03 | 130.0% |
Champions Oncology Reports Q1 FY26 Revenue of $14.0 Million
04 May 2026 · 4 May, 9:06 am
Summary
Champions Oncology announced its financial results for the first quarter of fiscal year 2026, ended July 31, 2025. Total revenue was $14.0 million, and adjusted EBITDA was $60,000. While revenue was slightly lower than the first quarter of last year, the company achieved solid sequential growth. The company anticipates continued topline expansion and margin improvement driven by a healthy services pipeline and growing demand for proprietary data offerings.
Key Highlights
- 1
Champions Oncology reported total revenue of $14.0 million for the first quarter of fiscal year 2026.
- 2
The company's adjusted EBITDA was $60,000 for the first quarter of fiscal year 2026.
- 3
Service revenue declined by $400,000, or 3%, compared to the same period last year.
- 4
Data license revenue increased by $300,000 compared to the same period last year.
- 5
The company reported a loss from operations of $527,000 for the first quarter of fiscal 2026.
- 6
Net cash provided by operating activities was approximately $600,000 for the quarter.
- 7
The company ended the quarter with approximately $10.3 million in cash and no debt.
Management Comments
Rob Brainin
It is great to be joining Champions at such an exciting inflection point. Our core services business—the backbone of our company—is strengthening and well positioned for sustained growth. At the same time, we are scaling our emerging data platform, which has already shown encouraging traction with leading biopharma partners. These complementary growth engines give us the opportunity to deepen our scientific impact, deliver innovative solutions to patients and customers, and create durable long-term value for shareholders. In parallel, our Corellia team continues to generate data demonstrating the potential of the compounds in our pipeline. Over the coming quarters, I look forward to working closely with our talented team to sharpen our strategy, invest in key capabilities, and build on Champions’ culture of collaboration and scientific excellence.
David Miller
We opened the fiscal year with $14 million in revenue and adjusted EBITDA of $60,000. While revenue was slightly lower than the first quarter of last year, we achieved solid sequential growth that met our expectations and provides a strong foundation for the year. As we move forward, we anticipate continued topline expansion and margin improvement driven by a healthy services pipeline and growing demand for our proprietary data offerings. Our financial Exhibit 99.1discipline and focus on profitable growth give us the flexibility to invest in strategic initiatives that will position Champions for long-term success.
Informational and educational content only. Not investment advice.